Summary Background The 2016 World Health Assembly endorsed the elimination of
hepatitis B virus (HBV) infection as a public health threat by 2030; existing therapies and …

Abstract Background Hepatitis B virus (HBV) infection is a global public health burden,
affecting nearly 300million people around the world. Due to HBV population is considered to …

There are 82 million people living with hepatitis B (PLWHB) in the World Health
Organization Africa region, where it is the main cause of liver disease. Effective vaccines …

Background China, which has the largest chronic hepatitis B virus (HBV) burden, may
expand antiviral therapy to attain the World Health Organization (WHO)-2030 goal of 65 …

Background & Aims The comparative risk of hepatocellular carcinoma (HCC) in patients with
chronic hepatitis B (CHB) receiving tenofovir disoproxil fumarate (TDF) vs. entecavir (ETV) …

Reducing hepatitis B virus (HBV) mother-to-child transmission (MTCT) is a fundamental step
toward the HBV elimination goal. The multicentred, multilevel SHIELD program aimed to use …

Background and Aims Despite widespread vaccination against hepatitis B and availability of
antiviral drugs, hepatitis B remained a major global public health problem. Therefore, an …

China has the world's largest burden of Hepatitis B virus (HBV) infection, with 86 million HBV
carriers, including 32 million chronic Hepatitis B patients. To monitor the HBV prevalence in …

The WHO African region bears a disproportionate burden of morbidity and mortality related
to chronic hepatitis B virus (HBV) infection and accounts for an estimated 70% of new HBV …

Nucleos (t) ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but
they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at …